{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:40:45Z","timestamp":1759538445387,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Mesalazine agents are essential drugs for treating ulcerative colitis (UC). Biomarkers that can differentiate mesalazine intolerance from exacerbated UC are needed because of the similarity of their symptoms and increasing prevalence of mesalazine intolerance. The study aim was to assess the usefulness of proteinase 3 antineutrophil cytoplasmic antibody (PR3-ANCA) to identify mesalazine intolerance in patients with UC. Methods: In this single-center retrospective study, patients with UC in whom serum PR3-ANCA was measured were included, and the serum levels were compared between the mesalazine-intolerant and -tolerant patient groups. The predictability of the marker to discriminate between these patients was analyzed. Results: Among 406 patients with UC with measured serum PR3-ANCA levels, 68 (17%) had mesalazine intolerance. The PR3-ANCA levels were significantly higher in the intolerance group than in the tolerance group [4.5 U\/mL (0.8\u201326.2 U\/mL) vs. 1.5 U\/mL (0.0\u20138.5 U\/mL), p = 0.001]. The area under the curve of the receiver operating characteristic curve analysis of the predictability of PR3-ANCA in differentiating mesalazine-intolerant patients from clinically active patients with UC was 0.755 (95% confidence interval: 0.634\u20130.876, cutoff value: 15.05 U\/mL; sensitivity: 0.625, specificity: 0.813). Multivariate logistic regression analysis using various clinical factors revealed that serum PR3-ANCA &gt; 15.0 U\/mL was an independent risk factor of mesalazine intolerance (odds ratio: 8.25, 95% confidence interval: 2.52\u201327.02, p &lt; 0.001). Conclusions: Serum PR3-ANCA could be a useful marker to identify mesalazine-intolerant patients with UC.<\/jats:p>","DOI":"10.3390\/jcm14197019","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T14:18:28Z","timestamp":1759501108000},"page":"7019","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elevated Serum Protease 3 Antineutrophil Cytoplasmic Antibody in Mesalazine-Intolerant Ulcerative Colitis: A Potential Diagnostic Biomarker"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9536-6678","authenticated-orcid":false,"given":"Yuhei","family":"Oyama","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1870-1863","authenticated-orcid":false,"given":"Takashi","family":"Taida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"},{"name":"Endoscopy Center, Chiba University Hospital, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Mukai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushi","family":"Koshibu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Ozeki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Furuya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiyo","family":"Mamiya","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Nakazawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Horio","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satsuki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akane","family":"Kurosugi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Sonoda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsubasa","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3691-8115","authenticated-orcid":false,"given":"Yuki","family":"Ohta","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Okimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4341-8135","authenticated-orcid":false,"given":"Keiko","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba 260-8677, Japan"},{"name":"Endoscopy Center, Chiba University Hospital, Chiba 260-8677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Eckmann","year":"2012","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_3","first-page":"3204","article-title":"Current treatment of ulcerative colitis","volume":"17","author":"Meier","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: Ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Yasutomi, E., Hiraoka, S., Yamamoto, S., Oka, S., Hirai, M., Yamasaki, Y., Inokuchi, T., Kinugasa, H., Takahara, M., and Harada, K. (2019). Switching between three types of mesalazine formulation and sulfasalazine in patients with active ulcerative colitis who have already received high-dose treatment with these agents. J. Clin. Med., 8.","DOI":"10.3390\/jcm8122109"},{"key":"ref_6","first-page":"CD000544","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","volume":"8","author":"Murray","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/jgh.15138","article-title":"Multicenter survey on mesalamine intolerance in patients with ulcerative colitis","volume":"36","author":"Hiraoka","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.5217\/ir.2018.00015","article-title":"5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis","volume":"16","author":"Miyoshi","year":"2018","journal-title":"Intest. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2015.09.001","article-title":"Correlation between concentrations of fecal calprotectin and outcomes of patients with ulcerative colitis in a phase 2 trial","volume":"150","author":"Sandborn","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3748\/wjg.v16.i9.1110","article-title":"Prediction of flare-ups of ulcerative colitis using quantitative immunochemical fecal occult blood test","volume":"16","author":"Kuriyama","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ajg.2012.315","article-title":"Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test","volume":"108","author":"Nakarai","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ecco-jcc\/jjw132","article-title":"Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis","volume":"11","author":"Shinzaki","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5217\/ir.2018.16.2.273","article-title":"Evaluation of the drug-induced lymphocyte stimulation test for diagnosing mesalazine allergy","volume":"16","author":"Saito","year":"2018","journal-title":"Intest. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5009\/gnl210211","article-title":"Role of serum proteinase 3 antineutrophil cytoplasmic antibodies in the diagnosis, evaluation of disease severity, and clinical course of ulcerative colitis","volume":"16","author":"Imakiire","year":"2022","journal-title":"Gut Liver"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/jgh.14140","article-title":"Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease","volume":"33","author":"Takedatsu","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Aoyama, Y., Inaba, T., Takahashi, S., Yasuhara, H., Hiraoka, S., Morimoto, T., Colvin, H.S., Wato, M., Ando, M., and Nakamura, S. (2021). Anti-proteinase 3 antineutrophil cytoplasmic antibody reflects disease activity and predicts the response to steroid therapy in ulcerative colitis. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-01903-5"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000515361","article-title":"Serum PR3-ANCA is a predictor of primary nonresponse to anti-TNF-\u03b1 agents in patients with ulcerative colitis","volume":"6","author":"Yoshida","year":"2021","journal-title":"Inflamm. Intest. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ejim.2004.08.007","article-title":"Bilateral pulmonary infiltrates in a patient with ulcerative colitis receiving mesalazine","volume":"15","author":"Nanayakkara","year":"2004","journal-title":"Eur. J. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"jjaf106","DOI":"10.1093\/ecco-jcc\/jjaf106","article-title":"ECCO-ESGAR-ESP-IBUS guideline on diagnostics and monitoring of patients with inflammatory bowel disease: Part 1: Initial diagnosis, monitoring of known inflammatory bowel disease, detection of complications","volume":"19","author":"Kucharzik","year":"2025","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"otab007","DOI":"10.1093\/crocol\/otab007","article-title":"Full, partial, and modified permutations of the mayo score: Characterizing clinical and patient-reported outcomes in ulcerative colitis patients","volume":"3","author":"Naegeli","year":"2021","journal-title":"Crohn\u2019s Colitis 360"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5217\/ir.2019.00084","article-title":"5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis","volume":"18","author":"Mizuno","year":"2020","journal-title":"Intest. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000527452","article-title":"Significance of 5-aminosalicylic acid intolerance in the clinical management of ulcerative colitis","volume":"104","author":"Mikami","year":"2023","journal-title":"Digestion"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Andaluc\u00eda, C., Mart\u00ednez-Prat, L., Bentow, C., Aure, M.A., Horn, M.P., and Mahler, M. (2023). Clinical validity of anti-proteinase 3 antibodies in patients with inflammatory bowel disease: A short meta-analysis. Diagnostics (Basel), 13.","DOI":"10.3390\/diagnostics13243682"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Matsumoto, S., and Mashima, H. (2020). Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-79207-z"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/apt.16120","article-title":"5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis","volume":"53","author":"Hibiya","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","article-title":"Pathogenesis and therapeutic interventions for ANCA-associated vasculitis","volume":"15","author":"Nakazawa","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11926-022-01088-0","article-title":"A spotlight on drug-induced vasculitis","volume":"24","author":"Yaseen","year":"2022","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/03009740701607117","article-title":"Can sulfasalazine therapy induce or exacerbate Wegener\u2019s granulomatosis?","volume":"37","author":"Denissen","year":"2008","journal-title":"Scand. J. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1111\/j.1572-0241.2000.03360.x","article-title":"Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis","volume":"95","author":"Bantel","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"ref_32","first-page":"41","article-title":"Update on the management of ulcerative colitis: Treatment and maintenance approaches focused on MMX(\u00ae) mesalamine","volume":"4","author":"Nanda","year":"2012","journal-title":"Clin. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200039020-00001","article-title":"Clinical pharmacokinetics of slow release mesalazine","volume":"39","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2036.2003.01408.x","article-title":"Systematic review: The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis","volume":"17","author":"Sandborn","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/ibd\/izab004","article-title":"Genetic background of mesalamine-induced fever and diarrhea in japanese patients with inflammatory bowel disease","volume":"28","author":"Suzuki","year":"2022","journal-title":"Inflamm. Bowel Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/19\/7019\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T14:25:55Z","timestamp":1759501555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/19\/7019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":35,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jcm14197019"],"URL":"https:\/\/doi.org\/10.3390\/jcm14197019","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]}}}